Anuh Pharma (506260) Q4 02/03 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 02/03 earnings summary
23 Oct, 2026Executive summary
FY ended 31 Mar 2003: net sales and operating income rose 11.6% YoY to ₹356.7m; PAT eased to ₹38.5m from ₹39.8m.
Directors recommended a ₹12.50/share dividend, up from ₹10/share, and expected satisfactory turnover and profit growth in FY04.
Financial highlights
Gross sales and operating income ₹371.2m vs ₹338.2m; net sales and operating income ₹356.7m vs ₹319.5m.
Other income ₹15.0m vs ₹15.6m; total income ₹371.8m vs ₹335.1m.
PBT ₹52.3m vs ₹49.5m; PAT ₹38.5m vs ₹39.8m.
Manufacturing cost rose to ₹272.4m from ₹233.6m; selling and administrative expenses increased to ₹27.9m from ₹20.6m.
Proposed dividend ₹8.7m, or ₹12.50/share, vs ₹6.96m, or ₹10/share; ₹25m transferred to general reserve vs ₹30m.
Outlook and guidance
Management expected stable product markets and satisfactory turnover and profit growth in FY04, supported by productivity initiatives and stringent cost controls.
Latest events from Anuh Pharma
- Sales and exports grew as the new Tarapur API facility came on stream.506260
Q4 06/07 - Profit rose despite weaker sales; a 1:1 bonus issue and 50% dividend were proposed.506260Q4 97/98
- Profit rose despite falling sales, with export growth and deposit-compliance concerns.506260Q4 98/99
- Sales rose 50% and exports climbed to Rs 99.03m as PAT reached Rs 24.34m.506260Q4 99/00
- PAT rose to ₹39.80m as exports grew and Tarapur capacity expansion began.506260Q4 01/02
- Sales rose 50.1%, exports 46.5%, and PAT reached Rs 60.3m in FY04.506260Q4 03/04
- Profit fell amid export weakness; a new factory targets ~70% more capacity.506260Q4 04/05
- Sales rose 49.14%, PAT grew 41.57%, and the new factory came on stream.506260Q4 05/06
- FY08 sales rose 35%, PAT grew 13.29%, and 150 MT of capacity was planned.506260Q4 07/08